13/09/2017 22:27:41

Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer

Related content
14 Nov - 
Veloxis Pharmaceuticals Announces Financial Results for..
31 Oct - 
Veloxis Pharmaceuticals A/S Grants Warrants Under Exist..
30 Sep - 
Veloxis Announces the Total Number of Shares and Voting..
Related debate
17 Nov - 
Nej, ingenlunde. Jeg troede bare du anklagede mig for a..
17 Nov - 
Undskyld, så har jeg ikke formuleret mig klart. Veloxis..
17 Nov - 
Godt set. Det lyder rigtigt i mine ører og forklarer at..

Company Release no. 19/2017

   

To: NASDAQ Copenhagen A/S                                     Copenhagen, Denmark, 13 September 2017

   

Veloxis Pharmaceuticals, Inc., Appoints Ulf Meier-Kriesche, MD, as Chief Scientific Officer

 

Veloxis Pharmaceuticals A/S is pleased to announce that Veloxis Pharmaceuticals, Inc. has hired Ulf Meier-Kriesche, MD, to serve as its Chief Scientific Officer.  In this role, Dr. Meier-Kriesche will oversee the Company’s regulatory and medical affairs departments.

Dr. Meier-Kriesche is a board certified Nephrologist with over 20 years of practical clinical experience in transplantation.  He is the author of over 170 scientific publications that have appeared in numerous peer-reviewed journals.  Additionally, Dr. Meier-Kriesche served on the faculty of the University of Florida Medical School from 2001 until 2011.   

Prior to joining Veloxis, Dr. Meier-Kriesche was the Clinical Trials Lead Immunology at Bristol-Myers Squibb.  Dr. Meier-Kriesche has also worked for Astellas Pharma.    

Craig Collard, CEO of Veloxis Pharmaceuticals A/S said “Veloxis is committed to serving the needs of the transplant community and the appointment of Ulf Meier-Kriesche further solidifies that commitment.  Ulf’s background and experience as a transplant nephrologist will help Veloxis be more responsive to the concerns of clinicians and ultimately better support the transplant community.”

Ulf Meier-Kriesche commented “I am thrilled to join Veloxis because of the wonderful opportunity we have together to bring new therapeutic options to transplant patients.”

 

For more information, please contact:

Craig A. Collard            

President & CEO                      

Phone: +1 919 591 3090                     

Email: cac@veloxis.com                      

 

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  

For further information, please visit www.veloxis.com.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
14 Nov
VELO
https://clinicaltrials.gov/ct2/show/NCT03321656?term=Veloxis&recrs=ab&rank=2
10
17 Nov
VELO
Har lyttet til webcastet igen. Craig Collard siger direkte, at salg til de novo kommer til at ske - ..
5
15 Nov
VELO
   Det er helt korrekt de har brugt 12 af lånerammens 15 mio$ Og dermed kun har 3 mio$ tilbage. Men ..
5
14 Nov
VELO
Highlights Record product revenue of tUSD 5,924 achieved in Q3 2017. Revenue reached tUSD 22,092..
5
15 Nov
VELO
  De sidste måneder har markedet vist stor usikkerhed, ift. hvilken retning udviklingen af forretnin..
4
17 Nov
VELO
  Der ligger rent faktisk et studie bagved, hvor hovedgruppen af de 25% udgør -  alder> 65, sort rac..
3
16 Nov
VELO
En udvikling her den sidste halve time. Gik fra 0,89 til 0,955 for så alligevel at lukke lidt i rødt..
3
15 Nov
VELO
Hej DJKS Vil lige indskyde, at der naturligvis ikke er salgstal fra nye markeder endnu, da de før..
3
14 Nov
VELO
God regnskabsdag derude. Lad os håbe det bliver med pil op :)
3
17 Nov
VELO
  Jeg er måske umulig og forstå skriftlig, hvis det er sådan du opfatter, hvad fremlægges :-) Naturl..
2

Alliance Trust PLC : Net Asset Value(s)

17/11/2017 13:20:40
ALLIANCE TRUST PLC                                    At the close of business on Thursday 16 November 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 778.8p -       including income, 788.4p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding i..

Dimensional Fund Advisors Ltd. : Form 8.3 - Tesco Plc - Ordinary shares

17/11/2017 10:28:48
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Alliance Trust PLC : Net Asset Value(s)

16/11/2017 14:31:51
ALLIANCE TRUST PLC                                    At the close of business on Wednesday 15 November 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 773.4p -       including income, 782.9p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
VR Resources Provides Corporate Update
2
Cuba Ventures Corp. Blockchain Revolupay identifies CCU Coin Cryptocurrency Data mining center in the Bahamas for possible synergy. CEO Steve Marshall meets with CEO of Stonegate Bank USA.
3
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ford Motor Company of Class Action and Upcoming Deadline – F
4
Doubletree By Hilton Carson Offers Active Duty Military And Veterans An Extra 20 Percent Off ‘Los Angeles Chargers Room And Ride’ Package; Supports Chargers ‘Salute To Service’ On November 19
5
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Trivago N.V., Inc. of Class Action Lawsuit and Upcoming Deadline – TRVG

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 November 2017 00:44:18
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171108.1 - EUROWEB3 - 2017-11-18 01:44:18 - 2017-11-18 00:44:18 - 1000 - Website: OKAY